Evidence map›Paper›PMID 42192183›Full record

ArticleScientific reports2026

YK-4-250 mitigates gastrointestinal radiation syndrome and promotes overall survival following partial body radiation injury.

Vidya P Kumar, Yali Kong, Kan Wang, Asa R Britton-Jenkins, Stanton Dulan, Landon L Moore, Debra Saunders, Randal May, Rheal Towner, Sanchita P Ghosh and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Vidya P Kumar *Armed Forces Radiobiology Research Institute, Bethesda, MD, 20814, USA.
Yali Kong *Department of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Lewis Hall, 700 W. Olney Rd., Norfolk, VA, 23507, USA.
Kan WangDepartment of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Lewis Hall, 700 W. Olney Rd., Norfolk, VA, 23507, USA.
Asa R Britton-JenkinsDepartment of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Lewis Hall, 700 W. Olney Rd., Norfolk, VA, 23507, USA.
Stanton DulanDepartment of Biological Sciences, Oakwood University, Huntsville, AL, 35896, USA.
Landon L MooreDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Debra SaundersDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Randal MayDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Rheal TownerDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Sanchita P GhoshArmed Forces Radiobiology Research Institute, Bethesda, MD, 20814, USA.
Courtney W HouchenDepartment of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.
Milton L BrownDepartment of Biomedical and Translational Sciences, Macon & Joan Brock Virginia Health Sciences at Old Dominion University, Lewis Hall, 700 W. Olney Rd., Norfolk, VA, 23507, USA. brownml@odu.edu.

Funding

National Institute of Allergy and Infectious Diseases AAI-12044-001-04000
6 · The paper itself

Abstract

Acute gastrointestinal radiation syndrome (GI-ARS) is a significant health threat following high-dose ionizing radiation (IR) exposure, leading to severe morbidity and mortality. The syndrome is characterized by gastrointestinal tissue damage caused by angiotensin II (Ang II) and reactive oxygen species (ROS), resulting in impaired GI function, systemic bacteremia, multi-organ failure, and eventual death. Dysregulation of the renin-angiotensin system (RAS) via Ang II exacerbates ROS production through activation of the Angiotensin II type 1 receptor (AT1R). This underscores the need for agents capable of both scavenging ROS and inhibiting AT1R activity. To address this, we developed YK-4-250, a Tempol-conjugated angiotensin receptor blocker (TCARB). YK-4-250 selectively inhibits the AT1R and exhibits antioxidant properties like Tempol and has a no observed adverse effect level (NOAEL) greater than 100 mg/kg. A single daily oral dose of 20 mg/kg of YK-4-250, administered either prior to or after 50% lethal dose (LD

Indexed as

Acute Radiation SyndromeGastrointestinal TractRadiation-Protective AgentsAngiotensin IIAnimalsAntioxidantsCyclic N-OxidesMiceReactive Oxygen SpeciesSpin LabelsAngiotensin IIAntioxidantsCyclic N-OxidesRadiation-Protective AgentsReactive Oxygen SpeciesSpin LabelstempolAngiotensin IIAngiotensin receptor blockerAntioxidantRadiation mitigatorReactive oxygen species

Identifiers

PMID42192183
PMCPMC13434262

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.